"10.1371_journal.pone.0085258","plos one","2014-01-21T00:00:00Z","Henning Hagmann; Verena Bossung; Abdel Ali Belaidi; Alexander Fridman; S Ananth Karumanchi; Ravi Thadhani; Bernhard Schermer; Peter Mallmann; Guenter Schwarz; Thomas Benzing; Paul T Brinkkoetter","Division of Nephrology, Department of Internal Medicine and Center for Molecular Medicine, University of Cologne, Cologne, Germany; Department of Obstetrics and Gynecology, University of Cologne, Cologne, Germany; Department of Biochemistry, University of Cologne, Cologne, Germany; Howard Hughes Medical Institute and Department of Medicine, Beth Israel Deaconess Medical Center and Harvard Medical School, Boston, Massachusetts, United States of America; Division of Nephrology, Department of Medicine, Massachusetts General Hospital, Harvard Medical School, Boston, Massachusetts, United States of America","Conceived and designed the experiments: HH VB AAB SAK RT BS PM GS TB PTB. Performed the experiments: HH VB AAB AF. Analyzed the data: HH VB PTB. Contributed reagents/materials/analysis tools: HH AAB PTB. Wrote the paper: HH SAK TB PTB.","Dr. Thadhani is a co-inventor on patents (USPTO #7,344,892) related to the prediction of preeclampsia that has been out licensed to diagnostic companies and has financial interest in Aggamin LLC. Dr. Karumanchi is a co-inventor of multiple patents (USPTO #7,740,849; #7,407,658; #7,335,362; #7,344,892) related to angiogenic proteins for the diagnosis and therapy of preeclampsia. These patents have been licensed to multiple companies. Dr. Karumanchi reports having served as a consultant to Roche and Beckman Coulter and has financial interest in Aggamin LLC. The remaining authors report no conflicts. This does not alter the authors' adherence to all the PLOS ONE policies on sharing data and materials.","2014","01","Henning Hagmann","HH",11,TRUE,10,4,3,4,TRUE,TRUE,FALSE,0,NA,FALSE
